These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31207478)

  • 1. Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours.
    Lowe KL; Cole D; Kenefeck R; OKelly I; Lepore M; Jakobsen BK
    Cancer Treat Rev; 2019 Jul; 77():35-43. PubMed ID: 31207478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
    Bossi G; Buisson S; Oates J; Jakobsen BK; Hassan NJ
    Cancer Immunol Immunother; 2014 May; 63(5):437-48. PubMed ID: 24531387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
    Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
    Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ImmTACs for targeted cancer therapy: Why, what, how, and which.
    Oates J; Hassan NJ; Jakobsen BK
    Mol Immunol; 2015 Oct; 67(2 Pt A):67-74. PubMed ID: 25708206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designer T-cells and T-cell receptors for customized cancer immunotherapies.
    Legut M; Sewell AK
    Curr Opin Pharmacol; 2018 Aug; 41():96-103. PubMed ID: 29852403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
    Yu L; Wang J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 9. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
    Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redirected T cells in cancer therapy.
    Sangiolo D
    Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.
    Harper J; Adams KJ; Bossi G; Wright DE; Stacey AR; Bedke N; Martinez-Hague R; Blat D; Humbert L; Buchanan H; Le Provost GS; Donnellan Z; Carreira RJ; Paston SJ; Weigand LU; Canestraro M; Sanderson JP; Botta Gordon-Smith S; Lowe KL; Rygiel KA; Powlesland AS; Vuidepot A; Hassan NJ; Cameron BJ; Jakobsen BK; Dukes J
    PLoS One; 2018; 13(10):e0205491. PubMed ID: 30321203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
    Finn OJ
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies.
    Hammerl D; Rieder D; Martens JWM; Trajanoski Z; Debets R
    Trends Immunol; 2018 Nov; 39(11):921-936. PubMed ID: 30309702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
    Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
    Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
    Tay JC; Zha S; Wang S
    Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.